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Background: The optimal management of advanced laryngeal and hypopharyngeal cancers
(L&HC) must involve consideration of both survival and functional effect of the given treat-
ment approach. Despite over two decades of investigations of several treatment options,
including surgery, radiotherapy, chemotherapy or some combinations thereof, little consen-
sus exists as to which treatment offers the best survival, together with functional speech
and swallowing.
Aim: To determine predictive and prognostic value of p53, EGFr, Ki-67 in patients with
advanced laryngeal and hypopharyngeal cancer, treated with larynx preservation intent.
Materials and methods: Thirty-three patients received 2–3 cycles of induction chemotherapy
(ICHT) consisting of cisplatin and ﬂuoruracil and underwent subsequent radical radiother-
apy. Immunohistochemical analyzes of p53, EGFr and Ki-67 were performed.
Results: Response to ICHT was obtained in 24 patients (75%). Better response to ICHT was
correlated only with EGFr expression (p=0.04, RR=1.91). The 5-year loco-regional control
(LRC) and disease-speciﬁc survival (DSS) rates were 48% and 57%, respectively. The 5-year
larynx preservation rate was 68% in responders to ICHT compared to 21% in non-responders(p=0.02). It was also higher in patients without EGFr expression (but not signiﬁcantly,
p=0.43).
Conclusion: Lack of EGFr expression is a favorable predictive factor for response to ICHT.
have
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The optimal management of advanced squamous cell laryn-
geal and hypopharyngeal cancers (L&HC) must involve
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved
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consideration of both survival and functional effect of the
given treatment approach. Despite over two decades of inves-
tigations of several treatment options, including surgery,
radiotherapy, chemotherapy or some combinations thereof,
little consensus exists as to which treatment offers the best
survival, together with functional speech and swallowing.1
In the 1990s, a standard treatment option for patients with
advanced L&HC who wanted to preserve their voice and
swallowing was induction chemotherapy (ICHT) followed by
radiotherapy.2,3 The new standard of care was established
after publishing the results of RTOG 91-11 trial which showed
signiﬁcant increase in larynx preservation rate after radiother-
apy with concurrent cisplatin compared to ICHT followed by
radiotherapy or radiotherapy alone.4,5
In the above studies, ICHT was used as a predictor of
radiosensitivity. Selection criteria for patients who may ben-
eﬁt from combining chemotherapy with radiotherapy remain
an unresolved problem. Researchers are looking for new fac-
tors predicting chemosensitivity, radiosensitivity and ﬁnally,
chances of larynx preservation. Studies on a number ofmolec-
ular markers have been undertaken. One of these markers is
p53 protein (product of the p53 suppressor gene). Mutation
of p53 is the most common genetic alteration identiﬁed thus
far in human cancers, and it plays an important role in cell
proliferation control.6 Its role as a predictor of chemosensi-
tivity and radiosensitivity remains contradictory.7–9 Another
potential marker is epidermal growth factor receptor (EGFr).
Its expression, which exists in 80–100% of advanced head
and neck cancers, is connected with higher aggressiveness of
cancers.10–14 Inhibition of EGFr bymonoclonal antibody brakes
activation of tyrosine kinase which in turn leads to impair-
ment or even stopping of cell cycle. Combination of antibody
against EGFr with cisplatin or doxorubicin causes stronger
toxic effect than each of the compounds separately.15,16 It is
also proven that the blockade of EGFr by antibody increases
radiosensitivity of squamous cell cancer of the head and
neck.17,18 Cell cycle proliferation plays a very important role
in head and neck cancer. One of the most often mea-
sured markers of proliferation is Ki-67 antigen. Squamous
cell cancer of the head and neck generally shows increased
expression of this marker, but its predictive and prognos-
tic value remains unclear, especially in patients treated with
ICHT.19–23
2. Aim
The aim of this retrospective study is to determine predic-
tive and prognostic value of p53, EGFr, Ki-67 in patients with
advanced L&HC treated with larynx preservation intent.
3. Materials and methods
3.1. Patients and treatment
The data from 32 patients with advanced L&HC treated
between January 1988 and December 1997 were analyzed ret-
rospectively. All patients were unﬁt for surgery because of
advancement of the primary tumor or co-existing morbidi-
ties. All patients received 2–3 cycles of ICHT: 2–16 patientsdiotherapy 1 5 ( 2 0 1 0 ) 87–92
(50%), 3–16 patients (50%). Induction chemotherapy consisted
of cisplatin (100mg/m2 as a 1-h infusion on day 1) and ﬂuo-
rouracil (1000mg/m2 as a 24-h infusion on days 1–5). The cycle
was repeated every 4 weeks. After ﬁnishing ICHT, all patients
underwent subsequent radical radiotherapy. All patients were
irradiated using megavoltage unit. Total tumor dose was
62–72Gy (median 68Gy), fraction dose was 2.0Gy delivered 5
times a week, overall treatment time was 40–51 days (median
43 days).
3.2. Histologic and immunohistochemical assessment
Histologic and immunohistochemical analyses were per-
formed at the Pathology Department of the Oncology Center
in Cracow, basing on archival parafﬁn blocks. All immuno-
histochemical assays were performed using the unstained
5-m tissue sections. The sectionsweremounted on silanized
slides (Menzel-Glasser), baked for 1h at 650 ◦C and stored
at room temperature until used. Sections were de-parafﬁned
in xylene and rehydrated in alcohol. Endogenous peroxi-
dase was blocked with 0.3% H2O2 followed by two washes
in de-ionized water. For antigen retrieval, slides were treated
with citrate buffer (pH 6.0) in a microwave oven (560W),
cooled, washed in TRIS buffer and then incubated with
normal swine serum (DAKO X0901) 1:10. Slides for Ki-67
antigen visualization were additionally treated with trypsin
(DAKO S2012) 0.05% (5min). Primary antibodies were incu-
bated overnight at 40 ◦C in a humidity chamber (dilutions in
table below), followed by 15min of incubation with biotiny-
lated secondary antibody and 15min with streptavidin–HRP
complex (LSAB2/HRP kit, DAKO S3000) 10min. After wash-
ing in TRIS and water, counterstaining and differentiation
with 3% HCl in alcohol, the slides were washed in de-ionized
water, dehydrated in graded concentration of alcohol, cleared
in xylene and covered. Tumors were considered EGFR pos-
itive only if clear brown membrane staining was noticed.
Tumor cells were considered positive for Ki-67 only when
there was clear nuclear staining. The number of positively
staining tumor cells per 500 tumor cells was counted and
the percentage of positively staining cells was assessed.
Evaluation of the p53 reactions was based on staining inten-
sity and estimation of the percentage of positive tumor
cell nuclei. Results of histologic and immunohistochemical
assessment together with patients’ characteristics are shown
in Table 1.
3.3. Statistical methods
The criteria of assessment of the treatment results included:
1. Overall response to induction chemotherapy deﬁned as
complete (CR) or partial (PR) regression of the primary
tumor and metastatic lymph nodes, according to WHO
criteria.24
2. Loco-regional control (LRC).
3. Disease-speciﬁc survival (DSS).Analysis of dependence between assessed factors and
univariate analysis of inﬂuence of assessed factors on the
chance of achieving response to ICHT were performed using
reports of practical oncology and radiotherapy 1 5 ( 2 0 1 0 ) 87–92 89
Table 1 – Patients’ characteristics.
Factor No. of pts. %
Sex
Male 30 94
Female 2 6
Age (median 57 years, range 43–73)
<57 15 47
≥57 17 53
KPS
≤60 7 22
>60 25 78
Primary site
Larynx 30 88
Hypopharynx 2 12
T-stage
T3 10 31
T4 22 69
N-stage
N0 17 53
N1–3 15 47
Clinical stage
III 7 22
IV 25 78
Histologic grading
G1+G2 16 50
G3 16 50
EGFr status
No expression 21 66
Expression 11 34
p53 status
No expression 13 41
Expression 19 59
Ki-67 status (median 59%, range 13–97%)
<59% 18 56
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Table 2 – Response rates to ICHT in relation to analyzed
factors (Chi-square test of independence).
Factor No. of pts. Response to ICHT (%) p
Sex
Male 30 82
Female 2 50 0.49
Age
<57 15 72
≥57 17 88 0.17
KPS
≤60 7 59
>60 25 79 0.18
T-stage
T3 10 83
T4 22 76 0.51
N-stage
N0 17 81
N1–3 15 82 0.92
Clinical stage
III 7 82
IV 25 29 0.66
Histologic grading
G1+G2 16 71
G3 16 84 0.26
EGFr status
No expression 21 94
Expression 11 62 0.03
p53 status
No expression 13 87
Expression 19 83 0.89
Ki-67 status
<59% 18 77
≥59% 14 86 0.74
Abbreviations: no. of pts. – number of patients, KPS – Karnofsky per-≥59% 14 44
Abbreviations: no. of pts. – number of patients, KPS – Karnofsky per-
formance status, EGFr – epidermal growth factor receptor.
hi-square test of independence. Multivariate analysis was
erformed using the logistic model. Five-year LRC and DSS
ates were assessed using the Kaplan–Meier method. Dif-
erences between groups were compared with log-rank test.
he multivariate analysis was performed using the Cox pro-
ortional hazards regression model. All the results with p
alue ≤0.05 were considered statistically signiﬁcant. Statisti-
al analyses were performed using STATISTICA v.6.0 software
y StatSoft.
. Results
.1. Response to induction chemotherapy
esponse to ICHT was obtained in 24 patients (75%).
esponse rates to ICHT in relation to the analyzed fac-
ors are shown in Table 2. Signiﬁcantly higher response
as achieved in patients without EGFr expression. It was
onﬁrmed in multivariate analysis (logistic model). Patients
aving tumors without expression of EGFr present approx-formance status, ICHT – induction chemotherapy, EGFr – epidermal
growth factor receptor.
imately two times higher chance of responding to ICHT
(p=0.04, RR=1.91).
4.2. Loco-regional control and disease-speciﬁc survival
The follow-up time, i.e. time between the date of starting
treatment and the date of patient’s death or the last follow-
up, was 10–102 months (mean 43, median 42). During the
follow-up period 21 patients died – 13 because of primary
cancer, 8 because of other causes. The 5-year LRC and DSS
rates assessed using the Kaplan–Meier method were 48% and
57%, respectively. The differences in 5-year LRC and DSS rates
according to the analyzed factors compared with log-rank
test are shown in Table 3. Statistically signiﬁcant unfavorable
prognostic factors for LRC were: KPS≤60, lack of response to
ICHT, and EGFr expression. Statistically signiﬁcant unfavor-
able prognostic factors for DSSwere: KPS≤60, lack of response
to ICHT and lymph nodes involvement. Multivariate anal-
ysis using the Cox proportional hazards regression model,
shows unfavorable inﬂuence of lack of response to ICHT on
LRC (p=0.01; RR=5.48) as well as on DSS (p=0.03; RR=4.12).
90 reports of practical oncology and ra
Table 3 – The 5-year LRC and DSS according to the
analyzed factors (log-rank test).
Factor No. of pts. LRC (%) p DSS (%) p
Sex
Male 30 51 55
Female 2 39 0.85 51 0.62
Age
<57 15 43 56
≥57 17 59 0.07 71 0.07
KPS
≤60 7 13 15
>60 25 51 0.04 59 0.02
T-stage
T3 10 43 47
T4 22 55 0.44 64 0.75
N-stage
N0 17 53 67
N1–3 15 41 0.20 42 0.04
Clinical stage
III 7 43 51
IV 25 52 0.74 59 0.73
Response to ICHT
PR+CR 24 55 61
No response 8 17 0.03 33 0.02
Histological grading
G1+G2 16 46 45
G3 16 47 0.96 57 0.98
EGFr status
No expression 21 44 55
Expression 11 21 0.04 36 0.24
p53 status
No expression 13 53 58
Expression 19 22 0.28 36 0.20
Ki-67 status
<59% 18 58 69
≥59% 14 37 0.33 37 052
Abbreviations: no. of pts. – number of patients, LRC – loco-regional
control, DSS – disease-speciﬁc survival, KPS – Karnofsky perfor-
mance status, ICHT – induction chemotherapy, PR+CR – partial
response+ complete response, EGFr – epidermal growth factor
receptor.
inﬂuence of p53 on larynx preservation rates9,13 or relapse-
free survival.12 Only study done by VALCSG showed increasedRegional lymph nodes involvement was unfavorable prognos-
tic factor inﬂuencing DSS (p=0.01).
4.3. Larynx preservation and treatment failures
Larynx preservation rate after 5 yearswas 68% in patientswho
respond to ICHT, compared to only 21% in non-responders
(p=0.02). It was also higher in patients without EGFr expres-
sion (but not signiﬁcant, p=0.43). Treatment failures were
observed in 19 patients (59%). The most common causes of
failurewere: local failure or/and recurrence – 11 patients (35%),
regional failure or/and recurrence – 10 patients (31%). Of these
patients, 6 (6/19 – 33%) underwent salvage surgery. Distant
metastases developed in 2 patients (6%) – both in the lungs.diotherapy 1 5 ( 2 0 1 0 ) 87–92
5. Discussion
In this retrospective study we analyzed a homogenous group
of 32 patients with advanced L&H cancer. All patients received
the same type of ICHT. Subsequent treatment varied depend-
ing on response to ICHT and performance status.
Overall response to ICHT (75%) is similar to cited in the
literature.2–4,25 Lack of EGFr expression is the only inde-
pendent factor predicting response to ICHT in multivariate
analysis. There is no correlation of EGFr expression with
any other of the examined factors. There are no data in
the literature concerning correlation between p53, EGFr and
Ki-67 expression and response to ICHT in patients treated
with larynx preservation intent. To our knowledge, only one
retrospective study has been published on EGFr in larynx
preservation treatment involving ICHT.25 Unfortunately, the
authors did not mention the inﬂuence of EGFr on response
to ICHT. Some researchers suggest that EGFr concentration of
more than 100 fmol/mg of membrane protein predicts better
response to chemotherapy inhead andneck cancer patients.10
Others did not show any correlation between EGFr expres-
sion and the results of chemotherapy.11,14 Studies undertaken
by Veterans Affairs Laryngeal Cancer Study Group (VALCSG)
showed signiﬁcant increase in response rates to ICHT among
patients with tumors overexpressing p53 (89% compared to
74%, respectively).7,8 On the contrary, Etienne et al.14 observed
lower p53 expression in responders (p=0.06). On the other
hand, a study from Memorial Sloan-Kettering Cancer Cen-
ter revealed no inﬂuence of p53 on response to ICHT.9 We
observe decreased response rates to ICHT in patients with
Ki-67 expression in less than 59% of cells. The difference
reaches 10% but is statistically insigniﬁcant. After decades of
explorations, predictive and prognostic role of Ki-67 remains
unclear. There are no published data concerning its inﬂuence
on response to ICHT, especially in larynx preservation treat-
ment. It may be explained by the fact that Ki-67 is considered
to be a predictor of radiosensitivity rather than of chemosen-
sitivity. Even though the data are contradictory,19–22 some
authors suggest possible misinterpretation of Ki-67 expres-
sion. Cell proliferation varies in different parts of tumor, and
Ki-67 proves that a cell is in the proliferation phase rather than
indicate how fast that proliferation really is.26,27
Larynx preservation rate among our patients reaches 50%
after 5 years of follow-up. The lack of EGFr expression is the
only statistically signiﬁcant predicting factor for larynxpreser-
vation. Our results are comparable to those published in the
literature.2,3 Meta-analysis of randomized trial in head and
neck cancer showed only slightly better results.28 There is
only one retrospective study showing that among patients
receiving ICHTwith subsequent radiotherapy, thosewith EGFr
level equal or higher than 100 fmol/mg had signiﬁcantly worse
disease-free survival (22% compared with 53%).25 Some other
show increased rate of loco-regional recurrence rate correlated
with overexpression of EGFr.11,12,29 Reviewing the literature
we found that majority of researchers observe unfavorablelarynx preservation rates in those who overexpress p53 (74%
compared to 53%, p=0.03).7 The role of Ki-67 remains unclear.
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ogether with overexpression of p53 decrease local control
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hat low Ki-67 expression together with lower p53 expression
ncrease relapse-free survival rates. These different results
ay be explained in the same way as mentioned above. It
hould be also considered that the above-cited authors used
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Until now, the results from studies on biomarkers have
ad no impact on clinical practice, possibly because there
re no data from large trials that speciﬁcally estimate L&HC.
he published data are not homogenous, different meth-
ds of assessment are used which probably could account
or the conﬂicting data. Among recently published data are
hose from trials concerning larynx preservation treatment
ith new ICHT regimens including taxanes. The results are
ncouraging; low toxicity is connected with high rates of
arynx preservation.30,31 Results have been also presented
oncerning targeted therapy with antibody against EGFr
ombined with radiotheray.32 Although that trial was not
esigned for organ preservation, the results are promising.
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. Conclusion
ack of EGFr expression is a favorable predictive factor for
esponse to ICHT. Larynx preservation rate is higher in those
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